Co-Inventors
Shevach, Ethan
Natarajan, Kannan
Margulies, David
Applications
Therapeutics
Research Materials
Research Products
Human Cell Lines
Antibodies
This technology involves the discovery and characterization of a novel cell surface antigen uniquely expressed on activated T regulatory (Treg) cells, serving as a receptor for latent transforming growth factor beta-1 (TGF-β1). To explore its role in immune regulation, a specific monoclonal antibody was developed through immunization of hamsters, capable of recognizing this antigen with high specificity. This antibody facilitates the identification and isolation of activated human FOXP3+ Treg cells from mixed populations, offering a valuable tool for studying Treg cell functions and potentially for therapeutic applications. Biochemical assays confirm the antibody's specificity, able to bind both GARP-bound and unoccupied TGF-β1, showcasing its potential in immunoprecipitation and Biacore studies. This advancement represents a significant step in immunology, providing insights into Treg cell-mediated immune regulation and opening avenues for targeted therapies in autoimmune diseases and cancer.
Commercial Applications
The monoclonal antibody targeting the novel antigen on activated T regulatory cells holds promising potential for multiple applications. In research, it enables detailed studies on the role and mechanisms of Treg cells in immune regulation, contributing to a deeper understanding of immune tolerance and the pathogenesis of autoimmune diseases and cancer. Clinically, it offers a pathway to develop targeted therapies aimed at modulating Treg cell activity, providing new strategies for treating autoimmune disorders, enhancing cancer immunotherapy, and improving transplant outcomes. Additionally, its use in isolating specific Treg cell populations could facilitate the development of personalized medicine approaches, tailoring treatments to individual immune profiles.
Competitive Advantages
This monoclonal antibody technology stands out for its unparalleled specificity to an antigen on activated T regulatory cells, enabling precise cell identification and isolation. It uniquely targets both GARP-bound and unoccupied molecules, broadening its application in immunological research and therapy development. This specificity, combined with its potential in diverse biochemical assays, positions it as a superior tool for advancing studies in immune regulation and offering novel therapeutic avenues.
